Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01312441 · ClinicalTrials.gov registry record · Phase 4
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
A Phase 4 study, sponsored by Albany College of Pharmacy and Health Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01312441 is a Phase 4 study that was terminated before completion, run by Albany College of Pharmacy and Health Sciences. The registered enrollment target is 20 participants.
The verdict
NCT01312441, a Phase 4 study, was terminated before completion, sponsored by Albany College of Pharmacy and Health Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The prevalence of vitamin D deficiency increases as kidney function declines. As a result, many hemodialysis patients often have low levels of vitamin D. Recent evidence has shown that vitamin D supplementation may improve many aspects of poor health such as heart disease and inflammatory markers. The objectives of this study are to determine how supplementing dialysis patients with ergocalciferol increases vitamin D levels, how long vitamin D levels can be maintained after a 6 month treatment course, and to examine the effect of ergocalciferol on biomarkers of inflammation and vascular health.
Interventions
- DRUG Placebo
- DRUG Ergocalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01312441
The ClinicalTrials.gov registry entry for NCT01312441 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albany College of Pharmacy and Health Sciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01312441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01312441 about?
NCT01312441 is a clinical study titled "Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D". The prevalence of vitamin D deficiency increases as kidney function declines. As a result, many hemodialysis patients often have low levels of vitamin D. Recent evidence has shown that vitamin D supplementation may improve many aspects of poor health such as heart disease and inflammatory markers. T...
What is the current status of trial NCT01312441?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2011-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01312441?
The interventions under investigation include: Placebo (DRUG), Ergocalciferol (DRUG).
Who is sponsoring clinical trial NCT01312441?
This trial is sponsored by Albany College of Pharmacy and Health Sciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.